CHICAGO (Reuters) - A jury in Chicago on Thursday rejected an Illinois woman’s claim that the now discontinued heartburn drug Zantac caused her colon cancer, in the first trial out of thousands of ...

Walmart has become the latest store to halt sales of the popular heartburn treatment Zantac after health regulators warned about a potentially dangerous contaminant in the drug. The nation's largest ...

How do you explain one Zantac manufacturer kiboshing a favorable trend of defense verdicts and decisions – with a massive $2.2 billion settlement? The answer appears to lie with the whistleblower suit ...

Feb 16 (Reuters) - Lawyers for a man who alleges he developed bladder cancer after taking GSK Plc's (GSK.L), opens new tab heartburn drug Zantac urged a California judge on Thursday to allow expert ...

The French pharmaceutical company Sanofi says it has reached an agreement to resolve 4,000 cases in the U.S., in which plaintiffs are linking the discontinued heartburn drug Zantac — and its active ...

A jury in Chicago on Thursday rejected an Illinois woman’s claim that the now discontinued heartburn drug Zantac caused her colon cancer, in the first trial out of thousands of lawsuits making similar ...

The U.S. Food and Drug Administration announced Wednesday it is requesting manufacturers remove all prescription and over-the-counter ranitidine drugs from the market immediately. This is the latest ...

In December, a federal judge dismissed 50,000 Zantac cases because the scientific evidence establishing cancer causation didn’t pass legal muster. In March, a California state judge reached the ...

The drug Zantac can elevate the risk of a person developing cancer. The active ingredient, ranitidine, contains a contaminant called NDMA, which is a probable human carcinogen. The above information ...

GSK has been sued by an independent Connecticut laboratory that accused the drugmaker of defrauding the U.S. government and taxpayers by concealing cancer risks in Zantac, once a blockbuster heartburn ...

Shares of GSK, Sanofi and Haleon all sold off sharply this week amid investor fear over potential U.S. litigation charges focused on popular heartburn drug Zantac. This has been a known issue bumbling ...